Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
AssigneeShire Laboratories, Inc.
InventorsBeth A. Burnside, Rong-Kun Chang, Xiaodi Guo
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition comprising at least one pharmaceutically active agent that is pH dependent, at least one non-pH dependent sustained release agent, and at least one pH dependent agent that increases the dissolution rate of the at least one pharmaceutically active agent at a pH in excess of 5.5. Such compositions have minimized pH-dependent dissolution profiles or pH-independent dissolution profiles.
Claims41
A pharmaceutical composition, comprising:
- (a) at least one pharmaceutically active agent that is pH dependent, said pharmaceutically active agent being selected from the group consisting of guanfacine and guanfacine hydrochloride;
- (b) at least one non-pH dependent sustained release agent selected from the group consisting of ethylcellulose, cellulose acetate, vinyl acetate/vinyl chloride copolymers, acrylate/methacrylate copolymers, polyethylene oxide, hydroxypropyl methylcellulose, carrageenan, alginic acid and salts thereof, hydroxyethyl cellulose, hydroxypropyl cellulose, karaya gum, acacia gum, tragacanth gum, locust bean gum, guar gum, sodium carboxymethyl cellulose, methyl cellulose, beeswax, carnauba wax, cetyl alcohol, hydrogenated vegetable oils, and stearyl alcohol;
- and
- (c) at least one pH dependent agent that increases the rate of release of said at least one pharmaceutically active agent from the tablet at a pH in excess of 5.5.
A pharmaceutical composition, comprising:
- (a) at least one pharmaceutically active agent that is pH dependent, said pharmaceutically active agent being selected from the group consisting of anagrelide and anagrelide hydrochloride;
- (b) at least one non-pH dependent sustained release agent selected from the group consisting of ethylcellulose, cellulose acetate, vinyl acetate/vinyl chloride copolymers, acrylate/methacrylate copolymers, polyethylene oxide, hydroxypropyl methylcellulose, carrageenan, alginic acid and salts thereof, hydroxyethyl cellulose, hydroxypropyl cellulose, karaya gum, acacia gum, tragacanth gum, locust bean gum, guar gum, sodium carboxymethyl cellulose, methyl cellulose, beeswax, carnauba wax, cetyl alcohol, hydrogenated vegetable oils, and stearyl alcohol;
- and
- (c) at least one pH dependent agent that increases the rate of release of said at least one pharmaceutically active agent from the tablet at a pH in excess of 5.5.
A pharmaceutical composition, comprising:
- (a) anagrelide;
- (b) polyethylene oxide;
- (c) dibasic calcium phosphate;
- (d) microcrystalline cellulose;
- (e) a methacrylic acid copolymer;
- (f) glyceryl behenate;
- and
- (g) magnesium stearate.
A pharmaceutical composition, comprising:
- (a) Anagrelide hydrochloride;
- (b) polyethylene oxide;
- (c) dibasic calcium phosphate;
- (d) microcrystalline cellulose;
- (e) a methacrylic acid copolymer;
- (f) glyceryl behenate;
- and
- (g) magnesium stearate.
A pharmaceutical composition comprising anagrelide as an active agent and characterized in that said composition when administered to a patient produces less of the side effects usually associated with anagrelide.
A pharmaceutical composition, comprising:
- (a) guanfacine;
- (b) Hydroxypropyl Methylcellulose
- (c) Ammonio Methacrylate Copolymer
- (d) microcrystalline cellulose;
- (e) a methacrylic acid copolymer;
- (f) glyceryl behenate;
- (g) Fumaric Acid,
- (h) Lactose Monohydrate
- (i) Povidone;
- and
- (j) Crospovidone Granulated Blend.
A pharmaceutical composition comprising:
- (a) Guanfacine hydrochloride;
- (b) Hydroxypropyl Methylcellulose
- (c) Ammonio Methacrylate Copolymer
- (d) microcrystalline cellulose;
- (e) a methacrylic acid copolymer;
- (f) glyceryl behenate;
- (g) Fumaric Acid,
- (h) Lactose Monohydrate
- (i) Povidone;
- and
- (j) Crospovidone Granulated Blend.
Dependencies are inferred from the claim text.